Payment overview · 2025
General Payments
$406.36
21 reported records · 5 companies
Healthcare provider profile · identity verified
Michael Dennis Putman, MD
Allopathic & Osteopathic Physicians|Family Medicine · BIRMINGHAM, AL · NPI 1871848929
Verified facts
What the public records show
CMS Open Payments records show Michael Dennis Putman, MD received $406.36 in general payments during 2025 across 21 reported records.
PFIZER INC. accounted for 53.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Myrbetriq by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $215.75 | 53.1% | 17 | 2025 |
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $124.01 | 30.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.50 | 6.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.10 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.00 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $406.36 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $215.75 | 17 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $215.75 | 17 | 2025 |
Source payment records
|
|||||
| ESOPHYX Normalized: esophyx |
Device | Merit Medical Systems Inc | $124.01 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 785 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 626 | 151 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 554 | 103 |
| Omeprazole | Omeprazole | 422 | 102 |
| Zolpidem Tartrate | Zolpidem Tartrate | 387 | 63 |
| Gabapentin | Gabapentin | 381 | 95 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 332 | 83 |
| Potassium Chloride | Potassium Chloride | 326 | 78 |
| Montelukast Sodium | Montelukast Sodium | 323 | 78 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 279 | 61 |
| Furosemide | Furosemide | 270 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 260 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 57 |
| Losartan Potassium | Losartan Potassium | 247 | 66 |
| Alprazolam | Alprazolam | 231 | 30 |
| Allopurinol | Allopurinol | 226 | 57 |
| Promethazine Hcl | Promethazine Hcl | 208 | 41 |
| Ibuprofen | Ibuprofen | 193 | 56 |
| Meloxicam | Meloxicam | 181 | 48 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 180 | 38 |
| Lisinopril | Lisinopril | 177 | 44 |
| Trazodone Hcl | Trazodone Hcl | 177 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 175 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 173 | 41 |
| Buspirone Hcl | Buspirone Hcl | 171 | 44 |
| Mounjaro | Tirzepatide | 165 | 35 |
| Carvedilol | Carvedilol | 164 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 163 | 40 |
| Metformin Hcl Er | Metformin Hcl | 157 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 37 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 154 | 49 |
| Linzess | Linaclotide | 148 | 37 |
| Famotidine | Famotidine | 144 | 35 |
| Fluconazole | Fluconazole | 141 | 66 |
| Methocarbamol | Methocarbamol | 138 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 134 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 38 |
| Alendronate Sodium | Alendronate Sodium | 127 | 23 |
| Pregabalin | Pregabalin | 126 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 124 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 123 | 41 |
| Jardiance | Empagliflozin | 119 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 117 | 31 |
| Ezetimibe | Ezetimibe | 116 | 34 |
| Metformin Hcl | Metformin Hcl | 116 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 115 | 28 |
| Tramadol Hcl | Tramadol Hcl | 115 | 26 |
| Prednisone | Prednisone | 112 | 60 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 109 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 108 | 23 |
| Clonazepam | Clonazepam | 107 | 26 |
| Donepezil Hcl | Donepezil Hcl | 105 | 28 |
| Sertraline Hcl | Sertraline Hcl | 103 | 28 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 101 | 24 |
| Eliquis | Apixaban | 101 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 25 |
| Fenofibrate | Fenofibrate | 97 | 24 |
| Clonidine Hcl | Clonidine Hcl | 96 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 23 |
| Ozempic | Semaglutide | 90 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 22 |
| Azelastine Hcl | Azelastine Hcl | 82 | 27 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 82 | 56 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 21 |
| Januvia | Sitagliptin Phosphate | 80 | 14 |
| Celecoxib | Celecoxib | 78 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 78 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 20 |
| Atenolol | Atenolol | 71 | 18 |
| Chlorthalidone | Chlorthalidone | 70 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 70 | 16 |
| Eszopiclone | Eszopiclone | 69 | 13 |
| Levofloxacin | Levofloxacin | 68 | 49 |
| Meclizine Hcl | Meclizine Hcl | 64 | 24 |
| Bupropion Xl | Bupropion Hcl | 62 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 18 |
| Glimepiride | Glimepiride | 61 | 12 |
| Topiramate | Topiramate | 59 | 16 |
| Colchicine | Colchicine | 58 | 13 |
| Spironolactone | Spironolactone | 56 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 18 |
| Lorazepam | Lorazepam | 54 | 12 |
| Mupirocin | Mupirocin | 54 | 17 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 52 | 19 |
| Ketoconazole | Ketoconazole | 51 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 15 |
| Nystatin | Nystatin | 50 | 22 |
| Valacyclovir | Valacyclovir Hcl | 50 | 15 |
| Methylprednisolone | Methylprednisolone | 46 | 38 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 14 |
| Simvastatin | Simvastatin | 43 | 12 |
| Estradiol | Estradiol | 42 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 36 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 31 |
| Azithromycin | Azithromycin | 37 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Baclofen | Baclofen | 34 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 12 |
| Doxepin Hcl | Doxepin Hcl | 33 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 12 |
| Diazepam | Diazepam | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 12 |
| Trulicity | Dulaglutide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Trulance | Plecanatide | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lactated Ringers | Ringer's Solution,lactated | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $406.36 · 21 records | PFIZER INC. | Dexcom G6 Transmitter, ESOPHYX, KRYSTEXXA, NURTEC ODT, Veozah, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error